COVID-19: Reinfection human challenge trial underway


close up of medical professional administering vaccine Share on Pinterest
Scientists are planning a trial that will determine whether or not people who have had COVID-19 are now immune to the virus that causes it. STEVE PARSONS/Getty Images
  • Experts still have a lot to learn about the likelihood that people who have had COVID-19 can contract SARS-CoV-2 again.
  • Scientists at the University of Oxford in the United Kingdom have announced a human challenge trial to gather hard, precise data that will provide a better understanding of how reinfection works.
  • Under carefully controlled conditions and for research purposes, scientists will reinfect the participants in the study with the original SARS-CoV-2 variant.

All data and statistics are based on publicly available data at the time of publication. Some information may be out of date.

One of the things that experts still do not know much about is what happens when people who have recovered from COVID-19 have exposure to the SARS-CoV-2 virus again.

Scientists at the University of Oxford have announced a human challenge trial that will investigate the response of the human immune system to a second SARS-CoV-2 infection.

According to Shobana Balasingam, the vaccines senior research advisor at the Wellcome Trust — which is the organization funding the trial — “There are still many unknowns surrounding this virus, and human infections studies can enable us to learn a lot about COVID-19.”

“This study has the potential to transform our understanding by providing high quality data on how our immune system responds to a second infection with this virus.”

The trial has two phases, the first of which begins this month. The second phase is expected to begin this summer.

Helen McShane, a professor of vaccinology at the Department of Paediatrics at the University of Oxford, is the study’s chief investigator. She explains the value of challenge studies, saying, “Challenge studies tell us things that other studies cannot because, unlike natural infection, they are tightly controlled.”

“When we reinfect these participants, we will know exactly how their immune system has reacted to the first COVID infection, exactly when the second infection occurs, and exactly how much virus they got.”

“As well as enhancing our basic understanding, this may help us to design tests that can accurately predict whether people are protected.”

Prof. Johnathan Stoye, who is not involved in the investigation, is a virologist from the Francis Crick Institute in London, U.K. He also commented on the importance of such research, telling Medical News Today, “This is an extremely interesting and important area.”

“Well-documented cases of reinfection can have different consequences. There are clearly many open questions that probably can only be answered by approaches along these lines of this study.”

Prof. Stoye went on to commend the “bravery of the volunteers and medical professionals involved.”

The investigation’s first phase will determine the minimum dose of SARS-CoV-2 that causes reinfection. The researchers will be using the original variant of SARS-CoV-2 from Wuhan, China.

Up to 64 healthy volunteers, all aged 18–30 years, who had previously contracted SARS-CoV-2 will participate in this phase of the trial. Before reinfecting them, the investigators will ensure that the participants are completely fit and have completely recovered from their first SARS-CoV-2 infection to minimize their risk.

The scientists will divide the phase 1 participants into two groups. The first group, of 24 individuals, will have exposure to increasing amounts of the SARS-CoV-2 virus to establish the dosing threshold at which reinfection occurs. The researchers will then administer this optimal dose to the second group.

The study participants will isolate in a specially designed hospital suite for at least 17 days.

The research team will be responsible for their care and will administer a range of medical tests, including CT lung imaging and MRI heart scans. The individuals will only be able to leave the hospital suite when they no longer have the infection and are no longer infectious.

If anyone develops any symptoms of COVID-19, they will receive monoclonal antibodies.

The participants will take part in a…



News Read More: COVID-19: Reinfection human challenge trial underway

Get real time updates directly on you device, subscribe now.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.